Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 102, Issue 1, Pages 45-51Publisher
WILEY
DOI: 10.1002/cpt.583
Keywords
-
Categories
Funding
- intramural research program of the National Institutes of Health
Ask authors/readers for more resources
Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available